Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Down 5.2 %

NERV opened at $2.38 on Wednesday. The company has a 50 day moving average of $2.23 and a two-hundred day moving average of $2.54. Minerva Neurosciences has a 52-week low of $2.03 and a 52-week high of $13.49. The company has a market cap of $16.64 million, a P/E ratio of -5.41 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.